Clinical trial
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple…
NCT03224507 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT03224507 |
|---|---|
| Title | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma |
| Official title | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial |
| Acronym | MASTER |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Amgen Industry Janssen Scientific Affairs, LLC |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | KRdD followed by auto-HCT, KRdD only |
| Enrollment | 123 |
| Start date | Mar 14, 2018 |
| Primary completion | May 1, 2023 |
| Completion | Jun 30, 2023 |
| First posted | Jul 21, 2017 |
| Last update posted | Nov 24, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: